Skip to main content
Clinical Trials/NCT05527405
NCT05527405
Active, not recruiting
Not Applicable

Efficacy of Caregiver Training Program in Enhancing Caregiver and Patient Outcomes in Visual Mapping Assistive Technology

MapHabit, Inc.1 site in 1 country50 target enrollmentAugust 24, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer Disease
Sponsor
MapHabit, Inc.
Enrollment
50
Locations
1
Primary Endpoint
Change in User Interaction and Engagement from baseline at 6 months
Status
Active, not recruiting
Last Updated
7 months ago

Overview

Brief Summary

As part of Phase II of the NIH SBIR grant, the study will conduct a randomized controlled clinical trial in which the MapHabit system (MHS) will offer a caregiver training product that is linked to MHS, an Alzheimer's disease or related dementias (AD/ADRD) assistive technology product that uses visual maps to improve a patient's behavior and sense of autonomy. MapHabit's combined areas of focus, i.e., offer a single integrated product to address the caregiver and the person under this caregiver's care, are unique and will create a new standard in the field to reduce caregiver burden in the setting of caring for individuals with AD/ADRD. Additionally, the study will integrate enhanced user support modules, i.e., gamifying, dashboarding, and social networking, to improve the Caregiver Training Program (CTP) experience.The study will be a randomized controlled clinical trial, in which two conditions will be investigated: 1) control condition in which the MHS alone is incorporated in the participant's daily care and 2) experimental condition in which the MHS+CTP is implemented into the daily care received by participants. The sample size will be a total of 50 patient-caregiver dyads, 25 in each condition. The study duration will be a 6-month intervention.

Registry
clinicaltrials.gov
Start Date
August 24, 2024
End Date
December 31, 2025
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stuart Zola

Chief Scientific Officer

MapHabit, Inc.

Eligibility Criteria

Inclusion Criteria

  • Individual diagnosed with Alzheimer's disease or other related dementia (ADRD) in their mild to moderate stage of impairment
  • Participating caregiver of individual with dementia must be the primary caregiver
  • Proficient in English

Exclusion Criteria

  • Individual not diagnosed with ADRD
  • Participating caregiver of individual with dementia is NOT the primary caregiver
  • Not proficient in English

Outcomes

Primary Outcomes

Change in User Interaction and Engagement from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

18-item quality-of-life questionnaire (QoL-18) evaluates a range of participants' behaviors, including mood, engagement, and memory at the end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

Change in Zarit Burden Assessment Caregiver Strain instrument from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

18-item questionnaire assessing the various stresses caregivers experienced relating to caring for an individual with cognitive impairment. The total score ranges from 0-72, with a higher score reflecting higher stress and burden on the caregiver.

Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

Assesses an individual with dementia's ability to carry out activities of daily living. The total score ranges from 0-53, with a higher score representing better performance in completing activities of daily living by the individual with dementia.

Change in Quality of Life - 18 (QoL-18) from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

18-item quality-of-life questionnaire (QoL-18) evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

Change in Brief Quality of Life - 8 (QoL-8) from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

8-items selected from the Wisconsin Quality of Life Caregiver Questionnaire evaluated a range of participants' behaviors, including mood, engagement, and memory at the middle and end of the study compared to before the use of the MHS. The instrument is scored on a Likert Scale, ranging from 1-10. A higher number indicates better outcome.

Change in Caregiver Self-Assessment Questionnaire from baseline at 6 months

Time Frame: Pre-Post: The instrument will be administered to the participants at baseline, post-intervention (6 months)

12-item, caregiver self-report measure of stress levels

Secondary Outcomes

  • 2-item Satisfaction Scale (SS-2)(The instrument was administered to the participants after the completion of the study duration (i.e., assessed at 6 months))
  • Pain and Sleep Questionnaire(Pre-Post: The assessment will be administered at baseline, post-intervention (6 months))
  • Generalized Anxiety Disorder (GAD7) Scale(Pre-Post: The assessment will be administered at baseline, post-intervention (6 months))
  • Anger Management Scale(Pre-Post: The assessment will be administered at baseline, post-intervention (6 months))

Study Sites (1)

Loading locations...

Similar Trials